FDA Actions

Name: Relias Media
Price range: $

January 2, 2015

FDA Actions

The FDA has approved the first generic version of donepezil (Aricept^®) for the treatment of Alzheimer's disease. The new generic will be marketed as 5 mg and 10 mg orally disintegrating tablets, which dissolve on the tongue and do not need to be swallowed. Generic donepezil is expected to be available later this year.

An FDA advisory panel is recommending expansion of the indication for rosuvastatin (Crestor^®) to include patients with normal cholesterol levels and no history of cardiovascular disease. The recommendation is based on the JUPITER trial, which showed a reduction in cardiovascular risk in patients with normal LDL cholesterol but high C-reactive protein who were treated with rosuvastatin.

Post Date: January 2, 2015

Table of Contents

Financial Disclosure: None of the authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients

Subscription Publication

Books & Study Guides

Group & Site Licenses

State CME/CE Requirements